Inflammatory bowel disease consists of ulcerative colitis and Crohn's disease.
Ulcerative colitis is a diffuse mucosal inflammation limited to the colon while Crohn's disease is a patchy, transmural inflammation that occurs in any part of the gastrointestinal tract.
The ileum and colon are the most frequently affected sites.


  • IBD is confirmed by clinical evaluation and a combination of biochemical, endoscopic, radiologic, histologic and/or nuclear medicine based investigations
  • Specific diagnosis of UC or CD is not determined in about 5% of patients because they have features of both conditions; this is termed as IBD type unclassified (IBDU)


Severity Assessment of Ulcerative Colitis
  • Clinical severity and anatomical extent of an acute attack of UC determines the therapeutic approach
  • Disease severity can be assessed using several disease activity indices (eg Truelove and Witts criteria, Mayo Clinic index, Sutherland index)

Severity Assessment




Bloody stools/day

< 4*

4 or more if

≥ 6 and



< 90 bpm

≤ 90 bpm

> 90 bpm


< 37.5°C

≤ 37.8°C

> 37.8°C

Hemoglobin (Hgb)

> 11.5 g/dL

≥ 10.5 g/dL

< 10.5 g/dL

Erythrocyte Sedimentation Rate (ESR)

< 20 mm/hr

≤ 30 mm/hr

> 30 mm/hr

or C-reactive Protein (CRP)


≤ 30 mg/dL

> 30 mg/dL

Adapted from Dignass A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. 2012.
*Stools may be with or without blood according to the American College of Gastroenterology and the Japanese Society of Gastroenterology 

Severity Assessment of Crohn's Disease
  • CD severity is generally more difficult to determine than UC
  • Crohn’s Disease Activity Index (CDAI) and the Harvey-Bradshaw Index (HBI) are commonly used systems in describing disease severity

Mild-Moderate Disease (Corresponds to CDAI 150-220)

  • Patient is ambulatory
  • Able to tolerate oral alimentation with:
    • No manifestation of dehydration
    • No sign of toxicity (high fever, rigors, prostration)
    • No abdominal tenderness or painful mass
    • No intestinal obstruction
    • <10% weight loss

Moderate-Severe Disease (Corresponds to CDAI 220-450)

  • Fever
  • Significant weight loss (>10%)
  • Abdominal pain or tenderness
  • Intermittent nausea or vomiting (N/V) without obstructive findings
  • Significant anemia
  • May also refer to patients who failed to respond to treatment for mild-moderate disease

Severe-Fulminant Disease (Corresponds to CDAI >450)

  • High fever
  • Persistent vomiting
  • Evidence of intestinal obstruction
  • Rebound tenderness or involuntary guarding
  • Cachexia
  • Evidence of an abscess
  • Also describes patients with persistent symptoms despite outpatient treatment of corticosteroids or biologic agents


  • Complete patient history should include:
    • Recent travel history, intolerances to food, smoking history, sexual history, medication (including use of NSAIDs and antibiotics) and vaccination history, past medical history (eg tuberculosis, intestinal infection), family history
  • Onset and duration of symptoms
  • Stool frequency, consistency, urgency
  • Presence of extraintestinal manifestations (eg arthritis, osteoporosis, fractures, inflammatory ocular symptoms, thromboembolic symptoms, primary sclerosing cholangitis, secondary amyloidosis, erythema nodosum, pyoderma gangrenosum)
  • Presence of mood disorders

Physical Examination

  • General well being, pulse rate, blood pressure, temperature, BMI, hydration/nutritional status, check for anemia
  • Inspection of eyes, mouth, skin and joints for extraintestinal involvement
  • Abdominal tenderness or distension, palpable mass, perianal exam (eg presence of fissures and fistulas)
  • Digital rectal exam for anal strictures, mass

Laboratory Tests

  • CBC, LFT, serum albumin, ferritin, calcium, magnesium, vit B12 level
  • Electrolytes (as indicators of decreased absorption)
  • Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
  • Routine stool exam including checking for occult blood or fecal leukocyte and stool culture
  • Stool microbiologic testing for infectious diarrhea including Clostridium difficile toxin, Cytomegalovirus (CMV)
    • Should be considered in severe or refractory colitis
  • Fecal calprotectin to detect intestinal inflammation
  • HIV and TB testing for high-risk population

Serologic Markers

  • Occasionally helpful in identifying patients who are at higher risk for complications and in selected patients in whom no other pathologic or clinical feature differentiates between CD from UC
  • UC: Perinuclear antineutrophil cytoplasmic antibodies
  • CD: Anti-Saccharomyces cerevisiae antibodies, CBir 1 (an anti-flagellin antibody)
  • Not sufficiently sensitive nor specific to be used as screening or diagnostic tool



  • Should attempt to define the type of IBD, mention coexistent diagnosis or complications, and determine presence of dysplasia and its grade
  • UC: Mucosal separation, distortion and atrophy of crypts; acute and chronic inflammatory cells in the lamina propria, preferential homing of neutrophils to the crypt epithelium, increased number of plasma cells near crypt base
  • CD: May be suggested by noncaseating granulomas, transmural inflammation, microscopic focality but absence of these features does not exclude CD



  • May differentiate CD from UC in >85% of patients if used in conjunction with other diagnostic modalities
  • Used to assess disease extent and activity, to monitor response to therapy, and for surveillance of dysplasia or neoplasia
  • Biopsy is an important part of endoscopic exam
    • Differentiates CD from UC and excludes presence of other causes of colitis
    • May help in establishing the extent of inflammation which aids in determining the appropriate therapy and disease prognosis
    • Rectal biopsy for histology is recommended even in the absence of macroscopic changes


  • Should not be done in patients with severe colitis or suspected of toxic megacolon due to increased risk of perforation
  • CD: Findings of segmental or discontinuous colitis or patchiness, rectal sparing, involvement of the terminal ileum and right-sided colon, and anal or perianal disease
    • Presence of ulcers (discrete, aphthous or serpiginous), cobblestoning of mucosa, granulomata
  • UC: Findings of granularity, friability, ulceration of the rectal mucosa and the vascular pattern is lost, diffuse superficial inflammation, erosis, and ulcers
    • These changes, seen endoscopically and histologically, usually involves the distal rectum
  • Colonoscopy with ileoscopy may help distinguish true CD ileitis from backwash ileitis
  • At least 2 biopsies from 5 sites, including distal ileum and rectum, is recommended

Flexible Sigmoidoscopy

  • Performed when colonoscopy is considered high risk (eg fulminant colitis) or where there is higher risk of bowel perforation
  • In patients diagnosed with UC, it helps in assessing disease activity and in evaluating other causes of colitis during disease exacerbations

Capsule Endoscopy

  • A less invasive technique in diagnosing CD when ileoscopy and small bowel follow through are negative or unsuccessful
  • Contraindicated in CD patients with known or suspected high-grade strictures
  • Does not allow tissue sampling
  • Major concern on capsule retention limits its use

Endoscopic Ultrasonography (Rigid Scope or with Flexible Endoscopes)

  • It can accurately assess and characterize Crohn’s perianal fistula
  • Used in assessing disease activity of colitis and transmural disease

Radiologic Studies

  • Complements endoscopic techniques in the diagnosis of IBD

Abdominal Radiography

  • Excludes colonic dilatation, helps assess disease extent in UC or identify proximal constipation
  • In CD, it shows mass in the right iliac fossa or small bowel dilatation, obstruction or perforation

Barium Contrast Examinations

  • Eg small bowel follow-through (SBFT), small bowel enteroclysis (SBE)
  • Typically inferior to colonoscopy
  • Shows luminal narrowing with ulcerations, loop adhesions/separations, and circular fold thickening and alterations
  • SBE is 95% sensitive and 96.5% specific for small bowel diseases especially for early mucosal lesions
  • SBFT is safer and better in detecting gastroduodenal abnormalities as compared to SBE (67-72% accuracy in detecting inflammation)
  • Limitations: extraluminal extensions andbowel wall complications of CD


  • Excludes colonic dilatation, helps assess disease extent in UC and identify proximal constipation
  • A noninvasive, sensitive way of identifying thickened small bowel loops in CD
  • 79% sensitive, 93% specific for stenosis; 71-74% sensitive, 95-96% specific for fistula; 84% sensitive, 93% specific for abscess
  • May also identify abscess and free fluid in peritoneum
  • Also used as an imaging guide during procedures
  • Limitations: limited access to the proximal ileum and jejunum, transverse colon and rectum

Computed Tomography (CT)

  • The gold standard for the detection of extraluminal complications particularly abscess formation
    • UC: May show marked bowel wall thickening, although this finding is nonspecific
  • A better imaging tool against peristalsis and motion because of its rapid pacing
    • 92% sensitive, 100% specific for stenosis; 89% sensitive for inflammation; 70% sensitive, 97% specific for fistula; 85% sensitive, 95% specific for abscess
  • Produces results faster and is readily available as compared to MRI
  • Limitation: may require luminal distention and application of contrast media; carries a potential risk for radiation-induced malignancy

Magnetic Resonance Imaging (MRI)

  • A good imaging tool that limits motion and peristalsis due to its fast sequences
  • 89% sensitive, 94% specific for stenosis; 83% sensitive for inflammation; 76% sensitive, 96% specific for fistula; 86-100% sensitive, 93-100% specific for abscess; 76% sensitive, 96% specific for abscess/fistula/inflammation infiltrates in CD
  • Provides information about disease activity, detects extraluminal findings and wall complications, and helps distinguish between inflammatory and fibrotic stricturing
    • Preferred over CT to minimize cumulative risks of radiation
  • Limitation: Requires administration of contrast media

Nuclear Medicine/Scintigraphy

  • A technique that can identify disease extension and activity
  • Has lower radiation exposure; recommended for children
  • WBC scintigraphy is more sensitive for screening of IBD because of the application of radiolabeled leukocytes
    • There is not enough evidence to support the use of FDG-PET in post-treatment IBD patients

Disease Extent of Ulcerative Colitis

  • Anatomical extent of UC is assessed endoscopically

Distal Colitis (Left-sided Colitis)

  • Limited to below the splenic flexure and therefore may be reached by topical therapy

Extensive Colitis (Pancolitis)

  • Colitis that extends proximal to the splenic flexure and therefore requires systemic therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 13 Feb 2019
The Mandarin-speaking population in Singapore (SG) has deemed the translated Chronic Liver Disease Questionnaire (CLDQ) culturally acceptable, with only two items that needed revision in the finalized CLDQ-SG, according to a recent study.
Rachel Soon, 30 Sep 2016

Understanding the factors which induce visceral hypersensitivity (VH) in patients with functional gastrointestinal disorders (FGIDs) may help doctors manage patients and develop new treatments, says an expert.

Dr. Angela V. Ignacio, 21 Feb 2017
Administration of a probiotic appears to be a safe and effective therapeutic alternative for minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis, according to a Greek study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, China.